Date published: 2026-10-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

DIC CRISPR/Cas9 KO Plasmid (h): sc-417651

0.0(0)
Write a reviewAsk a question
Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • DIC CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the DIC genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    DIC CRISPR/Cas9 KO Plasmid (h)

    sc-417651
    20 µg
    $397.00

    Overview

    SLC25A10 encodes the mitochondrial dicarboxylate carrier (DIC), an inner membrane transporter that exchanges malate and succinate with inorganic phosphate, linking mitochondrial metabolite flux to cytosolic biosynthetic and redox demands. By regulating the availability of dicarboxylates, DIC influences anaplerosis, gluconeogenic and lipogenic precursor balance, and coordination of the TCA cycle with oxidative phosphorylation. Altered SLC25A10 activity has been associated with metabolic reprogramming and mitochondrial stress responses, making it relevant for studying pathways that couple nutrient utilization to mitochondrial function. As a mitochondrial carrier family member, DIC also provides a handle to interrogate how transport constraints shape ROS handling and proliferative metabolism in disease-relevant cell models.

    DIC CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SLC25A10 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SLC25A10 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SLC25A10 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish DIC protein expression.

    This CRISPR knockout system enables efficient generation of SLC25A10-deficient cell models for investigation of DIC signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting SLC25A10 exon(s) critical for DIC function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple SLC25A10 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by DIC CRISPR/Cas9 KO Plasmid (h) and DIC CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SLC25A10 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by DIC HDR Plasmid (h) and DIC HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SLC25A10 homology arms to support homology-directed repair at defined SLC25A10 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.